My watch list  

Development and validation of an HPLC method to determine metabolites of 5‐hydroxymethylfurfural (5‐HMF)

The food component 5‐hydroxymethylfurfural is supposed to have antioxidative properties and is therefore used as an acting agent in a novel anticancer infusion solution, named Karal®, and an oral supplementation. Previous studies showed that after oral and intravenous application, the substance is completely decomposed to its metabolites: 5‐hydroxymethylfuroic acid, 2,5‐furandicarboxylic acid, and N‐(hydroxymethyl)furoyl glycine. The formation of a fourth metabolite, namely 5‐sulphoxymethylfurfural, is still not clarified according to literature. Due to commercial unavailability, synthesis of 5‐sulphoxymethylfurfural was conducted and a synthesis procedure for N‐(hydroxymethyl)furoyl glycine had to be developed. Identification of the synthesised compounds was proven by LC‐MS and NMR. An appropriate HPLC method was established to obtain good separation of the four possible metabolic substances and 5‐hydroxymethylfurfural within 12 min via a HILIC column (150 × 4.6 mm, 5 μm) using a gradient grade system switching from mobile phase A (ACN/ammonium formate 100 mM, pH 2.35, 95:5, v/v) to mobile phase B (ACN/ammonium formate 100 mM, pH 2.35, 85:15, v/v). The procedure was afterward validated following ICH guidelines in terms of selectivity, linearity, precision, LOD, and LOQ.

Authors:   Magdalena Hardt‐Stremayr, Marketa Bernaskova, Stefanie Hauser, Olaf Kunert, Xinghua Guo, Janette Stephan, Josef Spreitz, Ernst Lankmayr, Martin G. Schmid, Reinhold Wintersteiger
Journal:   Journal of Separation Science
Year:   2012
Pages:   n/a
DOI:   10.1002/jssc.201200251
Publication date:   03-Sep-2012
Facts, background information, dossiers
More about Wiley
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE